AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the companies will initially progress four programmes, which utilise CSPC's AI-driven peptide drug discovery platform and its LiquidGel once-monthly dosing platform technology. CSPC will receive an […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!